Third Harmonic Bio Inc. (THRD)
3.54
-0.08 (-2.21%)
At close: Mar 25, 2025, 3:59 PM
3.58
1.30%
Pre-market: Mar 26, 2025, 04:00 AM EDT
-2.21% (1D)
| Bid | 3.3 |
| Market Cap | 159.28M |
| Revenue (ttm) | 911.69K |
| Net Income (ttm) | -42.75M |
| EPS (ttm) | -0.97 |
| PE Ratio (ttm) | -3.64 |
| Forward PE | -3.64 |
| Analyst | Hold |
| Ask | 3.77 |
| Volume | 244,916 |
| Avg. Volume (20D) | 618,396 |
| Open | 3.62 |
| Previous Close | 3.62 |
| Day's Range | 3.51 - 3.64 |
| 52-Week Range | 3.18 - 16.94 |
| Beta | 2.87 |
About THRD
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company wa...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 14, 2022
Employees 51
Stock Exchange NASDAQ
Ticker Symbol THRD
Website https://www.thirdharmonicbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for THRD stock is "Hold." The 12-month stock price forecast is $14, which is an increase of 296.04% from the latest price.
Stock Forecasts1 month ago
-30.11%
Third Harmonic Bio shares are trading lower after ...
Unlock content with
Pro Subscription
7 months ago
+11.6%
Third Harmonic shares are trading higher on continued strength after the company reported Q2 financial results yesterday. Also, Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $20.
